301 related articles for article (PubMed ID: 20467365)
1. Novel treatment modalities for Graves' orbitopathy.
Bartalena L; Lai A; Sassi L; Lombardi V; Dalle Mule I; Gandolfo M; Liparulo L; Azzolini C; Piantanida E; Tanda ML
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():210-6. PubMed ID: 20467365
[TBL] [Abstract][Full Text] [Related]
2. Perspectives in pharmacological management of Graves' hyperthyroidism and orbitopathy.
Bartalena L; Lai A; Tanda ML
Expert Rev Clin Immunol; 2008 May; 4(3):321-9. PubMed ID: 20476922
[TBL] [Abstract][Full Text] [Related]
3. [Novel treatment opportunities in Graves' orbitopathy].
Erdei A; Gazdag A; Bodor M; Berta E; Katkó M; Ujhelyi B; Steiber Z; Győry F; Urbancsek H; Barna S; Galuska L; Nagy VE
Orv Hetil; 2014 Aug; 155(33):1295-300. PubMed ID: 25109914
[TBL] [Abstract][Full Text] [Related]
4. Currently available somatostatin analogs are not good for Graves' orbitopathy.
Tanda ML; Bartalena L
J Endocrinol Invest; 2006 May; 29(5):389-90. PubMed ID: 16794359
[No Abstract] [Full Text] [Related]
5. Potential utility of rituximab for Graves' orbitopathy.
Salvi M; Vannucchi G; Beck-Peccoz P
J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today.
Krassas GE; Gogakos A; Boboridis K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():204-9. PubMed ID: 20467364
[TBL] [Abstract][Full Text] [Related]
7. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
Wiersinga WM
Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
[TBL] [Abstract][Full Text] [Related]
8. Advances in the pharmacological treatment of Graves' orbitopathy.
Ruchała M; Sawicka-Gutaj N
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):981-9. PubMed ID: 26966785
[TBL] [Abstract][Full Text] [Related]
9. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
Genere N; Stan MN
Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
[TBL] [Abstract][Full Text] [Related]
10. [Octreotide scintigraphy in thyroid orbitopathy].
Aguirre-Balsalobre F; Mengual-Verdú E; Muñoz-Acosta JM; Martínez-Caballero A; Caballero-Carpena O; Hueso-Abacens JR
Arch Soc Esp Oftalmol; 2007 Mar; 82(3):133-9. PubMed ID: 17357889
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Rituximab for the Treatment of Graves' Orbitopathy: A Meta-analysis of Randomized Controlled Trials.
Shen WC; Lee CH; Loh EW; Hsieh AT; Chen L; Tam KW
Pharmacotherapy; 2018 May; 38(5):503-510. PubMed ID: 29601105
[TBL] [Abstract][Full Text] [Related]
12. [Biological treatment options for Graves' ophthalmopathy].
El Fassi D; Nielsen CH; Hegedüs L
Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab.
Karasek D; Cibickova L; Karhanova M; Kalitova J; Schovanek J; Frysak Z
Endokrynol Pol; 2017; 68(5):498-504. PubMed ID: 28660988
[TBL] [Abstract][Full Text] [Related]
14. [Somatostatin analogue treatment in Graves' ophthalmopathy: a case report].
Coloma-González I; Mengual-Verdú E; Domínguez-Escribano JR; Hueso-Abancens JR
Arch Soc Esp Oftalmol; 2007 Jan; 82(1):51-4. PubMed ID: 17262238
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose Rituximab for Active Moderate to Severe Graves' Orbitopathy Resistant to Conventional Treatment.
Du Pasquier-Fediaevsky L; Andrei S; Berche M; Leenhardt L; Héron E; Rivière S
Ocul Immunol Inflamm; 2019; 27(5):844-850. PubMed ID: 29652204
[No Abstract] [Full Text] [Related]
16. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
17. Commentary: rituximab, adalimumab, etanercept, tocilizumab--are biologics the future for Graves' orbitopathy?
Bartalena L
Ophthalmic Plast Reconstr Surg; 2014; 30(5):420-3. PubMed ID: 25025391
[TBL] [Abstract][Full Text] [Related]
18. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
[TBL] [Abstract][Full Text] [Related]
19. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
Krassas GE; Gogakos A
J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M; Vannucchi G; Currò N; Campi I; Covelli D; Dazzi D; Simonetta S; Guastella C; Pignataro L; Avignone S; Beck-Peccoz P
J Clin Endocrinol Metab; 2015 Feb; 100(2):422-31. PubMed ID: 25494967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
